Loading...
Loading...
India's meropenem imports from BELGIUM total $257.7K across 2 shipments from 1 foreign suppliers. PFIZER SERVICE COMPANY BV leads with $257.7K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include PFIZER LIMITED. This corridor reflects India's pharmaceutical import demand for meropenem โ a concentrated sourcing relationship with select suppliers from BELGIUM.

PFIZER SERVICE COMPANY BV is the leading Meropenem supplier from BELGIUM to India, with import value of $257.7K across 2 shipments. The top 5 suppliers โ PFIZER SERVICE COMPANY BV โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | PFIZER SERVICE COMPANY BV | $257.7K | 2 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | PFIZER LIMITED | $257.7K | 2 | 100.0% |
Visual overview of India's meropenem BELGIUM to India import corridor โ top suppliers, destinations, pricing, and trade routes
BELGIUM โ India trade corridor intelligence
The Belgium to India trade corridor for pharmaceutical imports is currently stable. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently, with minimal congestion. Freight rates have remained consistent over the past year, and the exchange rate between the Indian Rupee (INR) and the Euro has shown moderate fluctuations, not significantly impacting the cost of imports.
The Indian government's Production Linked Incentive (PLI) scheme aims to boost domestic manufacturing and reduce import dependency. This policy has led to increased investments in local pharmaceutical production, including Meropenem formulations. However, the transition towards self-reliance is gradual, and imports from countries like Belgium continue to play a crucial role in meeting the immediate demand for high-quality Meropenem formulations.
India and Belgium share a strong trade relationship, with Belgium being a significant exporter of pharmaceutical products to India. There are ongoing discussions to enhance trade facilitation, including mutual recognition of Good Manufacturing Practices (GMP) and streamlined regulatory processes. These efforts aim to strengthen bilateral trade and ensure the availability of quality pharmaceutical products in the Indian market.
The landed cost of importing Meropenem formulations from Belgium to India includes the following components:
The per-unit landed cost will vary based on the FOB price and other factors but can be estimated by summing these components.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Meropenem into India, the foreign manufacturer must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). The product must be registered with the Central Drugs Standard Control Organisation (CDSCO), which involves submitting Form 40 or 41, along with a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare. The registration process includes providing stability data as per ICH guidelines for Zone IV, ensuring compliance with the Indian Pharmacopoeia standards. The timeline for import drug registration varies but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory reviews.
Imported Meropenem formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, including accelerated and long-term studies, must be provided to demonstrate product integrity under Indian climatic conditions. Port inspections by customs drug inspectors are mandatory to verify the authenticity and quality of the imported products. Failure to meet these requirements can result in shipment delays, rejections, or destruction of the goods.
Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of finished pharmaceutical formulations, including Meropenem. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, leading to a reduction in import dependency. Bilateral agreements between India and Belgium have facilitated smoother trade relations, but they have also introduced additional compliance requirements to ensure product quality and safety.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 17.10%
India imports finished Meropenem formulations primarily due to the need for patented or branded products not available domestically, specific dosage forms, and the inability of local manufacturers to meet certain quality standards. The market size for Meropenem in India is substantial, with imports accounting for a significant portion of the total demand. The reliance on imports is driven by the complexity of manufacturing Meropenem formulations and the stringent quality requirements imposed by Indian regulatory authorities.
The Basic Customs Duty (BCD) for Meropenem formulations under HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied, resulting in a total duty of 20%. The Integrated Goods and Services Tax (IGST) is applicable at 12%, calculated on the sum of the CIF (Cost, Insurance, and Freight) value plus the total duty. There are no exemptions or concessional rates for imports from Belgium.
Belgium's pharmaceutical industry is renowned for its high-quality standards and innovative formulations, making it a preferred source for Meropenem formulations in India. Belgium's adherence to international quality standards and its established reputation in the pharmaceutical sector provide a competitive advantage over other suppliers. While countries like China, Germany, and the United States also export Meropenem formulations to India, Belgium's consistent quality and reliability make it a favored choice among Indian importers.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Meropenem formulations from Belgium due to the high quality and reliability of Belgian pharmaceutical products. Belgium offers patented formulations and specialized dosage forms that are not available domestically. The advanced technology and stringent quality control measures employed by Belgian manufacturers ensure that the products meet international standards, making them a preferred choice for Indian importers.
Compared to other origins like China, Germany, and the United States, Belgium offers a unique combination of quality, innovation, and regulatory compliance. While China may offer lower prices, the quality and regulatory standards may not always align with Indian requirements. Germany and the United States provide high-quality products but may have higher costs and longer lead times. Belgium's competitive pricing, coupled with its adherence to international quality standards, positions it favorably in the Indian market.
Indian importers face several supply chain risks when sourcing Meropenem formulations from Belgium, including:
To mitigate these risks, importers should conduct thorough due diligence and maintain contingency plans.
To optimize procurement of Meropenem formulations from Belgium, Indian buyers should consider the following actionable points:
Import license checklist, document requirements, quality testing, and compliance
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Meropenem suppliers from BELGIUM to India include PFIZER SERVICE COMPANY BV. The leading supplier is PFIZER SERVICE COMPANY BV with import value of $257.7K USD across 2 shipments. India imported Meropenem worth $257.7K USD from BELGIUM in total across 2 shipments.
India imported Meropenem worth $257.7K USD from BELGIUM across 2 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Meropenem sourced from BELGIUM include PFIZER LIMITED. The largest buyer is PFIZER LIMITED with $257.7K in imports across 2 shipments.
The total value of Meropenem imports from BELGIUM to India is $257.7K USD, across 2 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists